Karyopharm Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application for selinexor plus ruxolitinib in patients with myelofibrosis. The submission draws primarily on the Phase 3 SENTRY trial, which examined whether adding selinexor to ruxolitinib affected spleen volume and symptom burden in patients who had received no prior Janus kinase (JAK) inhibitor.
Richard Paulson, President and Chief Executive Officer of Karyopharm, stated:
“FDA acceptance of our sNDA is a significant milestone in the development of selinexor for patients with myelofibrosis and marks an important step toward expanding selinexor’s impact and reach.”
Phase 3 SENTRY Trial Design
SENTRY enrolled 353 patients with myelofibrosis who had platelet counts greater than 100 × 10⁹/L at enrollment. Participants were randomly assigned in a 2:1 ratio to receive selinexor 60 mg once weekly plus ruxolitinib or placebo plus ruxolitinib. Both groups received ruxolitinib, allowing investigators to assess the effect of adding selinexor to the regimen.
The trial specified two co-primary endpoints that assessed different aspects of the disease over the first 24 weeks.
Spleen volume response at week 24. The endpoint was the proportion of patients who achieved a reduction in spleen volume of at least 35%, referred to as SVR35. Change in symptom burden over 24 weeks. The endpoint was the average change from baseline in absolute total symptom score (Abs-TSS) over 24 weeks.
The SENTRY results were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published simultaneously in the Journal of Clinical Oncology. The findings were also presented at the 2026 European Hematology Association Congress. Karyopharm’s November announcement focused on the filing and trial design. Numerical efficacy and safety results for SENTRY are available in the trial publication.
Treatment Context in Myelofibrosis
Myelofibrosis is a rare blood cancer in which scarring of the bone marrow interferes with healthy blood cell production. Progressive anemia can cause fatigue and weakness. Spleen enlargement can contribute to abdominal discomfort, pain under the left ribs, and early satiety. Patients may also experience night sweats and bone pain. Karyopharm’s release cites estimates of approximately 20,000 people living with myelofibrosis in the United States and 19,000 in the European Union.
Reshma Rangwala, chief medical officer and head of research at Karyopharm Therapeutics, said:
“Myelofibrosis patients continue to face a significant unmet need, with JAK inhibitors as the only approved class of therapy,”
Ruxolitinib belongs to that class. Selinexor is an oral inhibitor of exportin 1 (XPO1), a protein involved in transporting molecules out of the cell nucleus. Selinexor is already approved in the United States in combination regimens for certain adults with previously treated multiple myeloma. Karyopharm said selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis if the FDA authorizes the regimen.
Safety Data From Approved Selinexor Regimens
The safety figures in the announcement come from two multiple myeloma studies conducted with different selinexor combinations. The release also lists warnings for thrombocytopenia, neutropenia, gastrointestinal toxicity, hyponatremia, serious infection, neurological toxicity, embryo-fetal toxicity, and cataracts.
- BOSTON trial. Among patients who received selinexor with bortezomib and dexamethasone, serious adverse reactions occurred in 52%, and 19% discontinued treatment because of adverse reactions. Fatal adverse reactions occurred in 6% of patients within 30 days of their last treatment.
- STORM trial. Among patients who received selinexor with dexamethasone, serious adverse reactions occurred in 58%, and 27% discontinued treatment because of adverse reactions. Fatal adverse reactions occurred in 9%.
FDA Review Timeline for Selinexor Plus Ruxolitinib
The FDA set June 28, 2027, as the target action date under the Prescription Drug User Fee Act for selinexor plus ruxolitinib in myelofibrosis. Richard Paulson, the company’s president and chief executive officer, said the aim is to make selinexor plus ruxolitinib available to patients as soon as possible if the FDA approves the combination. Karyopharm said it plans to work with the FDA throughout the review and is preparing for a potential US launch so it can make the regimen available to patients if authorized.
You can also read: ASH 2026 Myelofibrosis Guidelines: New Recommendations for JAK Inhibitors, Anemia and Transplantation.

